human
recombin
fab
fragment
specif
spike
protein
sever
acut
respiratori
syndrom
coronaviru
sarscov
screen
human
fab
librari
gener
rna
peripher
lymphocyt
convalesc
sar
patient
among
randomli
pick
clone
fab
special
react
protein
enzymelink
immunosorb
assay
microneutr
test
show
one
clone
design
neutral
activ
vero
cell
sarscov
dna
sequenc
analysi
indic
lightand
heavychain
gene
fab
belong
famili
respect
neutral
test
purifi
demonstr
mgml
complet
inhibit
sarscov
activ
absenc
cytopath
effect
day
realtim
fluoresc
revers
transcriptionpcr
also
prove
neutral
capac
data
show
number
viru
copi
significantli
reduc
group
suggest
import
role
passiv
immunoprophylaxi
sar
viru
sever
acut
respiratori
syndrom
sar
broke
worldwid
effect
medicin
cure
diseas
previou
studi
show
sar
patient
could
make
great
progress
given
serum
convalesc
sar
patient
indic
gener
human
monoclon
antibodi
mab
sar
coronaviru
sarscov
may
help
passiv
immunoprophylaxi
sar
viru
spike
protein
protein
sarscov
import
target
neutral
antibodi
construct
human
antibodi
librari
phage
display
techniqu
use
protein
sarscov
target
screen
phage
antibodi
librari
studi
describ
gener
one
neutral
sarscovspecif
human
antibodi
fab
molecul
pan
select
combinatori
fab
librari
protein
quantit
analysi
bind
neutral
activ
fab
molecul
construct
fab
phage
display
librari
total
rna
extract
peripher
blood
lymphocyt
convalesc
sar
patient
rna
isol
kit
stratagen
mrna
revers
transcrib
cdna
use
oligo
dt
primer
gibcobrl
fd
segment
variabl
first
constant
domain
gene
lightchain
gene
amplifi
use
primer
specif
human
chain
gene
amplifi
chain
clone
phage
display
vector
describ
bjorl
et
al
ligat
product
transform
escherichia
coli
result
librari
clone
transform
expand
volum
liter
result
phage
recov
describ
previous
enrich
antigenbind
clone
pan
microtit
well
coat
overnight
l
purifi
sarscov
beij
strain
lysat
antigen
gml
block
step
bovin
serum
albumin
bsa
phosphatebuff
salin
pb
l
fab
phage
cfu
ml
ad
well
follow
incub
h
unbound
clone
wash
phosphatebuff
salin
solut
contain
tween
well
wash
first
round
pan
time
second
round
time
third
fourth
round
respect
bound
phage
elut
triethylamin
ph
immedi
neutral
tri
base
elut
phage
amplifi
infect
escherichia
coli
cultur
follow
superinfect
helper
phage
vc
pfu
third
fourth
round
biopan
phage
librari
biopan
recombin
spike
protein
sarscov
express
cell
store
use
last
round
pan
phagemid
dna
extract
overnight
cultur
vector
modifi
excis
coat
protein
iiiencod
gene
fragment
phage
propag
induct
fab
product
perform
essenti
previous
describ
bacteri
supernat
select
enzymelink
immunosorb
assay
elisa
protein
presenc
sspecif
fab
elisa
screen
specif
fab
clone
protein
carri
doubl
antibodi
sandwich
elisa
protocol
follow
rabbit
anti
serum
dilut
mm
sodium
carbon
buffer
ph
appli
microtit
plate
left
overnight
time
plate
coat
bsa
vero
cell
lysat
neg
antigen
control
coat
plate
block
bsa
pb
sarscov
lysat
antigen
ad
captur
protein
plate
incub
l
crude
fab
prepar
pb
h
titrat
studi
bind
activ
purifi
neutral
fab
clone
protein
plate
coat
recombin
protein
express
cell
block
bsapb
twofold
serial
dilut
purifi
fab
rang
mgml
mgml
ad
bind
activ
fab
detect
horseradish
peroxidaselabel
goat
antihuman
fab
antibodi
absorb
measur
optic
densiti
nm
viru
neutral
capac
assay
abil
fab
inhibit
sar
viru
infect
assay
microneutr
test
mnt
crude
fab
twofold
dilut
mgml
mgml
purifi
neutral
clone
mix
equal
volum
sarscov
pfuml
mixtur
incub
h
subsequ
inocul
l
tissu
cultur
plate
contain
confluent
vero
cell
monolay
adsorpt
h
well
first
overlaid
l
dulbecco
modifi
eagl
medium
supplement
fetal
calf
serum
mm
hepe
incub
humidifi
co
atmospher
day
incub
invert
microscop
use
examin
cell
appear
cytopath
effect
cpe
day
neutral
effect
determin
inhibit
cpe
well
contain
fab
molecul
titer
end
point
taken
highest
dilut
complet
neutral
infect
dose
viru
neg
control
supernat
vector
cultur
includ
neutral
assay
repeat
least
twice
reproduc
result
sequenc
analysi
nucleotid
sequenc
v
l
v
h
region
determin
primer
primer
sequenc
respect
express
purif
protein
v
h
v
l
gene
fragment
clone
vector
express
e
coli
protein
product
fab
purifi
pellet
supernat
cultur
affin
chromatographi
affin
column
gener
link
goat
antihuman
immunoglobulin
g
igg
cnbractiv
sepharos
accord
manufactur
instruct
pharmacia
biotech
crude
fab
prepar
dilut
pb
appli
column
bound
fab
molecul
elut
hclglycin
ph
neutral
immedi
tri
base
appropri
fabcontain
fraction
pool
dialyz
overnight
result
fab
prepar
analyz
fab
concentr
antigen
reactiv
neutral
activ
sarscov
draw
standard
curv
examin
feasibl
realtim
revers
transcriptionpcr
rtpcr
assay
test
neutral
capac
known
amount
sarscov
rna
pfu
extract
subject
realtim
rtpcr
first
total
rna
viru
control
group
test
group
mgml
isol
aliquot
cultur
supernat
first
day
sixth
day
viru
infect
realtim
rtpcr
assay
perform
follow
oper
instruct
novel
coronaviru
pcr
fluoresc
diagnost
kit
piji
biolog
co
amplif
condit
min
min
follow
cycl
cycl
abi
sequenc
detector
use
analyz
fluoresc
emit
amplif
relationship
cycl
threshold
c
known
number
viru
copi
use
per
reaction
drawn
standard
curv
standard
curv
viru
copi
control
group
test
group
calcul
softwar
four
round
pan
coloni
randomli
pick
collect
crude
fab
supernat
contain
crude
fab
directli
subject
analysi
bind
activ
mean
doubl
antibodi
sandwich
elisa
fab
clone
specif
protein
select
optic
densiti
nm
posit
neg
ratio
among
clone
analyz
clone
appear
exhibit
bind
activ
specif
protein
neutral
capac
fab
clone
test
mnt
determin
evalu
percentag
cell
show
cpe
compar
viru
control
well
cell
observ
invert
microscop
day
incub
specif
cpe
consist
round
slough
infect
cell
monolay
seen
viru
control
well
occur
cell
day
chang
clearcut
cell
sheet
becom
almost
complet
disrupt
consist
open
meshwork
distort
cell
cpe
occur
cell
test
group
well
contain
fab
mia
viru
percentag
cpe
much
lower
viru
control
group
cell
show
cpe
day
show
cpe
day
tabl
find
indic
crude
could
partial
neutral
activ
sarscov
reduc
cpe
day
infect
pfu
sarscov
sequenc
analysi
dna
sequenc
analysi
confirm
lightand
heavychain
gene
fab
belong
famili
respect
amino
acid
sequenc
variabl
region
deduc
dna
sequenc
shown
tabl
express
purif
protein
sinc
use
crude
fab
mnt
assay
gave
weak
neutral
activ
due
low
content
fab
e
coli
cultur
protein
express
ml
cultur
purifi
affin
chromatographi
order
confirm
quantit
analyz
neutral
capac
nonreduc
polyacrylamid
gel
electrophoresi
assay
fig
show
degrad
ran
singl
band
expect
r
use
antihuman
fab
antibodi
confirm
major
fab
present
elut
fraction
fig
concentr
final
yield
purifi
mg
equival
mgliter
bacteri
supernat
analysi
antigen
bind
activ
purifi
protein
elisa
identifi
bind
specif
fab
molecul
protein
elisa
perform
coat
well
recombin
protein
test
antigen
cell
lysat
bsa
use
neg
antigen
control
figur
show
much
stronger
reactiv
protein
control
antigen
analysi
neutral
capac
purifi
toward
sarscov
microneutr
test
mtt
assay
util
test
effect
vero
cell
prolifer
cell
treat
dilut
mgml
mgml
show
differ
control
data
shown
serial
dilut
mgml
mgml
subject
mnt
neutral
capac
purifi
determin
observ
compar
differ
cpe
appear
test
group
viru
control
group
day
appear
cpe
cell
shown
fig
summar
tabl
figur
tabl
demonstr
cpe
appear
cell
cell
expos
mgml
cell
show
cpe
day
infect
pfu
viru
find
indic
display
neutral
capac
start
concentr
mgml
postpon
occurr
cpe
day
titer
end
point
mgml
complet
neutral
activ
sarscov
cpe
appear
day
neutral
capac
detect
realtim
rtpcr
assay
feasibl
realtim
rtpcr
assay
test
neutral
capac
examin
detect
viru
copi
control
group
test
group
mgml
linear
standard
curv
obtain
subject
known
amount
sarscov
rna
realtim
rtpcr
result
indic
amount
input
rna
increas
c
requir
reach
threshold
fluoresc
detect
decreas
linear
relationship
found
c
rna
copi
number
determin
correl
coeffici
r
shown
fig
indic
accuraci
assay
assay
strongli
support
notion
result
realtimertpcr
could
sensit
reflect
number
viru
copi
use
reaction
rna
viru
control
group
test
group
mgml
collect
subject
realtim
rtpcr
assay
initi
amount
viru
copi
determin
sd
softwar
version
abi
compani
neutral
activ
quantifi
compar
number
viru
copi
viru
control
group
test
group
shown
tabl
number
viru
copi
test
group
drop
much
viru
control
group
second
day
sixth
day
viru
infect
number
viru
copi
decreas
time
test
group
control
group
second
day
viru
infect
indic
neutral
capac
highli
infecti
diseas
sar
high
mortal
rate
caus
novel
coronaviru
sarscov
effect
antisar
drug
vaccin
therapi
avail
far
sinc
sarscov
brought
great
danger
human
be
develop
human
antisar
monoclon
antibodi
would
provid
use
passiv
immun
treatment
sar
patient
phage
display
techniqu
becom
power
tool
gener
human
antibodi
recent
easi
manipul
also
advantag
high
select
capac
studi
demonstr
feasibl
effici
way
obtain
rare
antibodi
complet
human
antibodi
directli
studi
strain
beij
use
antigen
pan
sinc
preval
serotyp
china
report
neutral
epitop
sarscov
locat
mainli
protein
howev
amount
protein
virus
small
compar
whole
viru
structur
protein
difficult
obtain
mab
neutral
capac
nonneutr
mab
problem
requir
modif
pan
screen
process
present
studi
lymphocyt
construct
antisarscov
fab
librari
deriv
convalesc
sar
patient
protect
titer
igg
sarscov
higher
detect
elisa
mnt
respect
also
use
highli
purifi
virion
first
two
round
pan
recombin
spike
protein
last
two
round
order
increas
possibl
select
neutral
fab
clone
fab
librari
elisa
data
confirm
purifi
bound
specif
protein
neutral
test
demonstr
mgml
could
postpon
occurr
cpe
day
upon
challeng
pfu
sarscov
titrat
end
point
mgml
complet
neutral
activ
sarscov
although
inhibitori
concentr
ic
could
precis
determin
mnt
could
estim
mnt
result
ic
rang
mgml
mgml
realtim
fluoresc
rtpcr
util
test
differ
number
sarscov
copi
group
treat
mgml
viru
control
group
studi
show
number
viru
copi
group
time
lower
control
previou
studi
demonstr
fab
molecul
could
protect
capac
vivo
absenc
fc
region
affin
constant
wholemolecul
igg
antigen
improv
time
compar
fab
scfv
molecul
form
therefor
structur
modif
may
increas
bind
affin
neutral
capac
studi
show
use
studi
conform
structur
immunogen
protein
furthermor
valuabl
passiv
immunoprophylaxi
sarscov
